Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.27 USD
-0.11 (-0.26%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $42.25 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
CERE 42.27 -0.11(-0.26%)
Will CERE be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CERE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CERE
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
CERE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
Other News for CERE
Tuesday Talk: Big-Tech Under Attack
Strike While The Market Is Hot
3 Potential Biotech Buyout Targets In 2024
Intra-Cellular Therapies Is On Fire
AbbVie: Comeback Expected After Humira Patent Expiration